CMV Colitis Not Responding to Ganciclovir: Management After First-Line Failure
This protocol applies to patients with cytomegalovirus (CMV) colitis that is not mild disease — specifically those for whom the standard first-line antiviral regimen did not achieve the expected clinical response, or where that regimen cannot be continued due to toxicity or resistance.
Clinical Scenario
The patient has CMV colitis classified as not mild disease. Oral antiviral therapy appropriate for mild presentations is not suitable in this setting. A structured, more intensive approach targeting full resolution of colitis signs and symptoms is required.
Previous Treatment & Failure Condition
The prior treatment line for moderate-to-severe CMV colitis used ganciclovir, with an option to transition to oral valganciclovir once oral absorption was possible. The therapeutic target of that regimen was resolution of signs and symptoms of CMV colitis within 21–42 days. This protocol applies when that target is not reached — whether due to insufficient clinical response, treatment-limiting toxicities, or resistance to the first-line agent.
Next-Line Approach (Overview)
When the first-line antiviral regimen for CMV colitis fails or cannot be tolerated, alternative intravenous antiviral agents are available. These require specific supportive measures administered alongside each infusion. The clinical goal remains resolution of CMV colitis signs and symptoms within 21–42 days. Full agent selection criteria, dosing schedule, and required co-administration details are contained in the structured protocol.
References
- IV ganciclovir is the therapy of choice (AI) and can be switched to oral valganciclovir once the person can tolerate and absorb oral medications, extrapolated from randomized, clinical trial data showing non-inferiority of oral valganciclovir for treatment of CMV disease in people receiving a solid organ transplant (SOT) (AIII).
- Oral valganciclovir can be used in patients with mild disease (AIII).
- 21–42 days or until signs and symptoms have resolved (AIII).
View source ↗